IOL CHEMICALS AND PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.2 INR | -2.76% |
|
-3.97% | -20.94% |
| 03-19 | IOL Chemicals Gets Zero Observations from Brazilian Health Regulatory Agency After Inspection of Units | MT |
| 02-19 | IOL Chemicals Gets Nod to Export Diabetes Drug to China | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.59 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.94% | 265M | - | ||
| +31.37% | 588B | B | ||
| -2.60% | 364B | C+ | ||
| +20.83% | 326B | B- | ||
| +5.69% | 285B | C+ | ||
| +14.83% | 239B | B+ | ||
| +9.93% | 210B | B- | ||
| -6.95% | 200B | A+ | ||
| +10.77% | 167B | C+ | ||
| +0.10% | 161B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IOLCP Stock
- Ratings IOL Chemicals and Pharmaceuticals Limited